Статті в журналах з теми "Tyrosine Kinase Inhibitors Targeting"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся з топ-50 статей у журналах для дослідження на тему "Tyrosine Kinase Inhibitors Targeting".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Переглядайте статті в журналах для різних дисциплін та оформлюйте правильно вашу бібліографію.
Deininger, Michael. "Targeting Tyrosine Kinase Receptors." Blood 122, no. 21 (November 15, 2013): SCI—25—SCI—25. http://dx.doi.org/10.1182/blood.v122.21.sci-25.sci-25.
Повний текст джерелаChen, Jin-Shuen, Li-Chien Chang, Shyh-Jer Huang, and Chao-Wen Cheng. "Targeting Spleen Tyrosine Kinase-Bruton’s Tyrosine Kinase Axis for Immunologically Mediated Glomerulonephritis." BioMed Research International 2014 (2014): 1–6. http://dx.doi.org/10.1155/2014/814869.
Повний текст джерелаForster, Michael, Xiaojun Julia Liang, Martin Schröder, Stefan Gerstenecker, Apirat Chaikuad, Stefan Knapp, Stefan Laufer, and Matthias Gehringer. "Discovery of a Novel Class of Covalent Dual Inhibitors Targeting the Protein Kinases BMX and BTK." International Journal of Molecular Sciences 21, no. 23 (December 4, 2020): 9269. http://dx.doi.org/10.3390/ijms21239269.
Повний текст джерелаManzo, Lawaly Maman, Moudirat Lawaly, and Lui YU. "Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-small cell lung cancer." Indian Journal of Pharmaceutical and Biological Research 3, no. 02 (June 30, 2015): 81–87. http://dx.doi.org/10.30750/ijpbr.3.2.10.
Повний текст джерелаCher, Chae Yin, Cheuk Him Man, Stephen S. Y. Lam, Eric S. K. Ho, Nelson K. L. Ng, Marie-Anne Hospital, Jerome Tamburini, and Anskar Y. H. Leung. "Targeting Polo-like Kinase in Acute Myeloid Leukemia." Blood 124, no. 21 (December 6, 2014): 2234. http://dx.doi.org/10.1182/blood.v124.21.2234.2234.
Повний текст джерелаGrimminger, Friedrich, Ralph T. Schermuly, and Hossein A. Ghofrani. "Targeting non-malignant disorders with tyrosine kinase inhibitors." Nature Reviews Drug Discovery 9, no. 12 (December 2010): 956–70. http://dx.doi.org/10.1038/nrd3297.
Повний текст джерелаPasquet, Jean-Max, Romain Gioia, Claire Drullion, Valerie Lagarde, Cedric Leroy, Serge Roche, Bruno Cardinaud, and Francois-Xavier Mahon. "Tyrosine Kinase Proteins profiling of Nilotinib Resistant Chronic Myelogenous Leukemia Cells Unravels a Tyrosine Kinase-Mediated Bypass." Blood 114, no. 22 (November 20, 2009): 2175. http://dx.doi.org/10.1182/blood.v114.22.2175.2175.
Повний текст джерелаSakle, Nikhil S., Shweta A. More, Sachin A. Dhawale, and Santosh N. Mokale. "Targeting Small Molecule Tyrosine Kinases by Polyphenols: New Move Towards Anti-tumor Drug Discovery." Current Drug Discovery Technologies 17, no. 5 (December 23, 2020): 585–615. http://dx.doi.org/10.2174/1570163816666190808120843.
Повний текст джерелаvan der Kuip, Heiko, Lara Wohlbold, Carsten Oetzel, Matthias Schwab, and Walter E. Aulitzky. "Mechanisms of Clinical Resistance to Small Molecule Tyrosine Kinase Inhibitors Targeting Oncogenic Tyrosine Kinases." American Journal of PharmacoGenomics 5, no. 2 (2005): 101–12. http://dx.doi.org/10.2165/00129785-200505020-00003.
Повний текст джерелаShojaee, Seyedmehdi, Maike Buchner, Huimin Geng, Bolland Silvia, Phillip Koeffler, and Markus Muschen. "Targeting Inhibitory Phosphatases in Tyrosine Kinase-Driven Leukemias." Blood 118, no. 21 (November 18, 2011): 1382. http://dx.doi.org/10.1182/blood.v118.21.1382.1382.
Повний текст джерелаDassonville, Olivier, Alexandre Bozec, Jean Louis Fischel, and Gerard Milano. "EGFR targeting therapies: Monoclonal antibodies versus tyrosine kinase inhibitors." Critical Reviews in Oncology/Hematology 62, no. 1 (April 2007): 53–61. http://dx.doi.org/10.1016/j.critrevonc.2006.12.008.
Повний текст джерелаLipsky, Andrew, and Nicole Lamanna. "Managing toxicities of Bruton tyrosine kinase inhibitors." Hematology 2020, no. 1 (December 4, 2020): 336–45. http://dx.doi.org/10.1182/hematology.2020000118.
Повний текст джерелаKutsch, Nadine, Reinhard Marks, Richard Ratei, Thomas K. Held, and Martin Schmidt-Hieber. "Role of Tyrosine Kinase Inhibitors in Indolent and Other Mature B-Cell Neoplasms." Biomarker Insights 10s3 (January 2015): BMI.S22434. http://dx.doi.org/10.4137/bmi.s22434.
Повний текст джерелаYamaoka, Toshimitsu, Sojiro Kusumoto, Koichi Ando, Motoi Ohba, and Tohru Ohmori. "Receptor Tyrosine Kinase-Targeted Cancer Therapy." International Journal of Molecular Sciences 19, no. 11 (November 6, 2018): 3491. http://dx.doi.org/10.3390/ijms19113491.
Повний текст джерелаLogie, Emilie, Chandra S. Chirumamilla, Claudina Perez-Novo, Priyanka Shaw, Ken Declerck, Ajay Palagani, Savithri Rangarajan, et al. "Covalent Cysteine Targeting of Bruton’s Tyrosine Kinase (BTK) Family by Withaferin-A Reduces Survival of Glucocorticoid-Resistant Multiple Myeloma MM1 Cells." Cancers 13, no. 7 (March 31, 2021): 1618. http://dx.doi.org/10.3390/cancers13071618.
Повний текст джерелаGarcía-Aranda, Marilina, and Maximino Redondo. "Targeting Receptor Kinases in Colorectal Cancer." Cancers 11, no. 4 (March 27, 2019): 433. http://dx.doi.org/10.3390/cancers11040433.
Повний текст джерелаK. Bhanumathy, Kalpana, Amrutha Balagopal, Frederick S. Vizeacoumar, Franco J. Vizeacoumar, Andrew Freywald, and Vincenzo Giambra. "Protein Tyrosine Kinases: Their Roles and Their Targeting in Leukemia." Cancers 13, no. 2 (January 7, 2021): 184. http://dx.doi.org/10.3390/cancers13020184.
Повний текст джерелаK. Bhanumathy, Kalpana, Amrutha Balagopal, Frederick S. Vizeacoumar, Franco J. Vizeacoumar, Andrew Freywald, and Vincenzo Giambra. "Protein Tyrosine Kinases: Their Roles and Their Targeting in Leukemia." Cancers 13, no. 2 (January 7, 2021): 184. http://dx.doi.org/10.3390/cancers13020184.
Повний текст джерелаStaudt, Dilana, Heather Murray, Tabitha McLachlan, Frank Alvaro, Anoop Enjeti, Nicole Verrills, and Matthew Dun. "Targeting Oncogenic Signaling in Mutant FLT3 Acute Myeloid Leukemia: The Path to Least Resistance." International Journal of Molecular Sciences 19, no. 10 (October 16, 2018): 3198. http://dx.doi.org/10.3390/ijms19103198.
Повний текст джерелаLevis, Mark, and Alexander E. Perl. "Gilteritinib: potent targeting of FLT3 mutations in AML." Blood Advances 4, no. 6 (March 24, 2020): 1178–91. http://dx.doi.org/10.1182/bloodadvances.2019000174.
Повний текст джерелаBaselga, José, and Carlos L. Arteaga. "Critical Update and Emerging Trends in Epidermal Growth Factor Receptor Targeting in Cancer." Journal of Clinical Oncology 23, no. 11 (April 10, 2005): 2445–59. http://dx.doi.org/10.1200/jco.2005.11.890.
Повний текст джерелаRendell, Aimee, Isobel Thomas-Bland, Lee McCuish, Christopher Taylor, Mudra Binju, and Yu Yu. "Targeting Tyrosine Kinases in Ovarian Cancer: Small Molecule Inhibitor and Monoclonal Antibody, Where Are We Now?" Biomedicines 10, no. 9 (August 29, 2022): 2113. http://dx.doi.org/10.3390/biomedicines10092113.
Повний текст джерелаPaatero, Ilkka, Ville Veikkolainen, Matias Mäenpää, Etienne Schmelzer, Heinz-Georg Belting, Lauri J. Pelliniemi, and Klaus Elenius. "ErbB4 tyrosine kinase inhibition impairs neuromuscular development in zebrafish embryos." Molecular Biology of the Cell 30, no. 2 (January 15, 2019): 209–18. http://dx.doi.org/10.1091/mbc.e18-07-0460.
Повний текст джерелаMelgar, Katelyn, Morgan M. Walker, LaQuita M. Jones, Lyndsey C. Bolanos, Kathleen Hueneman, Mark Wunderlich, Jian-Kang Jiang, et al. "Overcoming adaptive therapy resistance in AML by targeting immune response pathways." Science Translational Medicine 11, no. 508 (September 4, 2019): eaaw8828. http://dx.doi.org/10.1126/scitranslmed.aaw8828.
Повний текст джерелаOta, Yoko, Hiroyuki Yoda, Takahiro Inoue, Takayoshi Watanabe, Yoshinao Shinozaki, Atsushi Takatori, and Hiroki Nagase. "Targeting anaplastic lymphoma kinase (ALK) gene alterations in neuroblastoma by using alkylating pyrrole-imidazole polyamides." PLOS ONE 16, no. 9 (September 30, 2021): e0257718. http://dx.doi.org/10.1371/journal.pone.0257718.
Повний текст джерелаMoradpour, Zahra, and Leila Barghi. "Novel Approaches for Efficient Delivery of Tyrosine Kinase Inhibitors." Journal of Pharmacy & Pharmaceutical Sciences 22 (January 13, 2019): 37–48. http://dx.doi.org/10.18433/jpps29891.
Повний текст джерелаSos, Martin L., Hannah Lea Tumbrink, Carsten Schultz-Fademrecht, Jonas Lategahn, Marina Keul, Janina Niggenaber, Alena Heimsoeth, et al. "Targeting EGFR Ex20 mutant lung cancer with the wild type sparing kinase inhibitor PRB001." Journal of Clinical Oncology 37, no. 15_suppl (May 20, 2019): e14718-e14718. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.e14718.
Повний текст джерелаChase, Andrew, and Nicholas C. P. Cross. "Signal transduction therapy in haematological malignancies: identification and targeting of tyrosine kinases." Clinical Science 111, no. 4 (September 13, 2006): 233–49. http://dx.doi.org/10.1042/cs20060035.
Повний текст джерелаChew, Serena, Melissa C. Mackey, and Elias Jabbour. "Gilteritinib in the treatment of relapsed and refractory acute myeloid leukemia with a FLT3 mutation." Therapeutic Advances in Hematology 11 (January 2020): 204062072093061. http://dx.doi.org/10.1177/2040620720930614.
Повний текст джерелаAmelia, Tasia, Rahmana Emran Kartasasmita, Tomohiko Ohwada, and Daryono Hadi Tjahjono. "Structural Insight and Development of EGFR Tyrosine Kinase Inhibitors." Molecules 27, no. 3 (January 26, 2022): 819. http://dx.doi.org/10.3390/molecules27030819.
Повний текст джерелаAubry, Arthur, Stéphane Galiacy, and Michèle Allouche. "Targeting ALK in Cancer: Therapeutic Potential of Proapoptotic Peptides." Cancers 11, no. 3 (February 26, 2019): 275. http://dx.doi.org/10.3390/cancers11030275.
Повний текст джерелаHsu, Jonathan, Jun Zhang, Chris Kitson, Seng-Lai Tan, Satwant Narula, Julie A. DeMartino та Cheng Liao. "Development of a Pharmacodynamic Assay Based on PLCγ2 Phosphorylation for Quantifying Spleen Tyrosine Kinase (SYK)–Bruton’s Tyrosine Kinase (BTK) Signaling". Journal of Biomolecular Screening 18, № 8 (23 травня 2013): 890–98. http://dx.doi.org/10.1177/1087057113489881.
Повний текст джерелаAlcalá, Sonia, Víctor Mayoral-Varo, Laura Ruiz-Cañas, Juan Carlos López-Gil, Christopher Heeschen, Jorge Martín-Pérez, and Bruno Sainz. "Targeting SRC Kinase Signaling in Pancreatic Cancer Stem Cells." International Journal of Molecular Sciences 21, no. 20 (October 9, 2020): 7437. http://dx.doi.org/10.3390/ijms21207437.
Повний текст джерелаNelson, Erik A., Sarah R. Walker, Ellen Weisberg, Michal Bar-Natan, Rosemary Barrett, Laurie B. Gashin, Shariya Terrell, et al. "The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors." Blood 117, no. 12 (March 24, 2011): 3421–29. http://dx.doi.org/10.1182/blood-2009-11-255232.
Повний текст джерелаChen, Yun, Yao Guo, Wanting Ho, and Zhizhuang Joe. "Identification and Characterization Of a Potent FLT3 Inhibitor." Blood 122, no. 21 (November 15, 2013): 5027. http://dx.doi.org/10.1182/blood.v122.21.5027.5027.
Повний текст джерелаCapparelli, Claudia, Timothy Purwin, and Andrew Aplin. "Abstract B05: Sox10 differentially regulates receptor tyrosine kinase expression in melanomas." Cancer Research 80, no. 19_Supplement (October 1, 2020): B05. http://dx.doi.org/10.1158/1538-7445.mel2019-b05.
Повний текст джерелаThomas, Christan M., and Peter Campbell. "FLT3 inhibitors in acute myeloid leukemia: Current and future." Journal of Oncology Pharmacy Practice 25, no. 1 (September 30, 2018): 163–71. http://dx.doi.org/10.1177/1078155218802620.
Повний текст джерелаCho, Hyewon, Eun Lee, Hye Ah Kwon, Lee Seul, Hui-Jeon Jeon, Ji Hoon Yu, Jae-Ha Ryu, and Raok Jeon. "Discovery of Tricyclic Pyranochromenone as Novel Bruton’s Tyrosine Kinase Inhibitors with In Vivo Antirheumatic Activity." International Journal of Molecular Sciences 21, no. 21 (October 25, 2020): 7919. http://dx.doi.org/10.3390/ijms21217919.
Повний текст джерелаTyner, Jeffrey W., Stephanie Willis, Michael W. N. Deininger, and Brian J. Druker. "RNAi Functional Screening of the Tyrosine Kinome Identifies Therapeutic Targets in Acute Myeloid Leukemia Patients." Blood 110, no. 11 (November 16, 2007): 208. http://dx.doi.org/10.1182/blood.v110.11.208.208.
Повний текст джерелаOlsen, Colin E., Eric S. Gourley, Xiao-Hui Lui, Jeff Walker, Cory L. Grand, Steven L. Warner, Hariprasad Vankayalapati, and David J. Bearss. "Targeting the JAK2 Kinase in Hematological Malignancies." Blood 110, no. 11 (November 16, 2007): 3560. http://dx.doi.org/10.1182/blood.v110.11.3560.3560.
Повний текст джерелаPadi, Sathish Kumar Reddy, Libia A. Luevano, Ningfei An, Ritu Pandey, Neha Singh, Jin H. Song, Jon C. Aster, Xue-Zhong Yu, Shikhar Mehrotra, and Andrew S. Kraft. "Therapeutic Targeting of PIM Protein Kinases in a Subset of T-Cell Acute Lymphoblastic Leukemia." Blood 128, no. 22 (December 2, 2016): 2742. http://dx.doi.org/10.1182/blood.v128.22.2742.2742.
Повний текст джерелаManouchehri, Ali, Elishama Kanu, Michael J. Mauro, Aaron W. Aday, Jonathan R. Lindner, and Javid Moslehi. "Tyrosine Kinase Inhibitors in Leukemia and Cardiovascular Events." Arteriosclerosis, Thrombosis, and Vascular Biology 40, no. 2 (February 2020): 301–8. http://dx.doi.org/10.1161/atvbaha.119.313353.
Повний текст джерелаZheng, Tony J., Elizabeth R. Lofurno, Alexander R. Melrose, Hari Hara Sudhan Lakshmanan, Jiaqing Pang, Kevin G. Phillips, Meghan E. Fallon, et al. "Assessment of the effects of Syk and BTK inhibitors on GPVI-mediated platelet signaling and function." American Journal of Physiology-Cell Physiology 320, no. 5 (May 1, 2021): C902—C915. http://dx.doi.org/10.1152/ajpcell.00296.2020.
Повний текст джерелаNordigården, Amanda, Maria Kraft, Pernilla Eliasson, Verena Labi, Eric W. F. Lam, Andreas Villunger, and Jan-Ingvar Jönsson. "BH3-only protein Bim more critical than Puma in tyrosine kinase inhibitor–induced apoptosis of human leukemic cells and transduced hematopoietic progenitors carrying oncogenic FLT3." Blood 113, no. 10 (March 5, 2009): 2302–11. http://dx.doi.org/10.1182/blood-2008-07-167023.
Повний текст джерелаLeung, John SM. "Cost-effectiveness of epidermal growth factor receptor-targeting tyrosine kinase inhibitors." Hong Kong Medical Journal 20, no. 5 (October 8, 2014): 465. http://dx.doi.org/10.12809/hkmj144336.
Повний текст джерелаYu, Xiangfan, Simei Qiu, Dongshan Sun, Pei Guo, and Quhuan Li. "Comparison of Intermolecular Interactions of Irreversible and Reversible Inhibitors with Bruton’s Tyrosine Kinase via Molecular Dynamics Simulations." Molecules 27, no. 21 (November 2, 2022): 7451. http://dx.doi.org/10.3390/molecules27217451.
Повний текст джерелаWeatherald, Jason, Louise Bondeelle, Marie-Camille Chaumais, Christophe Guignabert, Laurent Savale, Xavier Jaïs, Olivier Sitbon, et al. "Pulmonary complications of Bcr-Abl tyrosine kinase inhibitors." European Respiratory Journal 56, no. 4 (June 11, 2020): 2000279. http://dx.doi.org/10.1183/13993003.00279-2020.
Повний текст джерелаWei, Jia, Ling Ma, Chenglong Li, Christopher R. Pierson, Jonathan L. Finlay, and Jiayuh Lin. "Targeting Upstream Kinases of STAT3 in Human Medulloblastoma Cells." Current Cancer Drug Targets 19, no. 7 (August 2, 2019): 571–82. http://dx.doi.org/10.2174/1568009618666181016165604.
Повний текст джерелаLv, Jiahui, Jingde Wu, Feng He, Ying Qu, Qiuqiong Zhang, and Chenggong Yu. "Development of Bruton’s Tyrosine Kinase Inhibitors for Rheumatoid Arthritis." Current Medicinal Chemistry 25, no. 42 (February 6, 2019): 5847–59. http://dx.doi.org/10.2174/0929867325666180316121951.
Повний текст джерелаHu, Chunqi, and Xiaowu Dong. "Cysteine-targeted Irreversible Inhibitors of Tyrosine Kinases and Key Interactions." Current Medicinal Chemistry 26, no. 31 (November 19, 2019): 5811–24. http://dx.doi.org/10.2174/0929867325666180713124223.
Повний текст джерела